MTGR1 Products

Description

Chimera RNA interference (chimera RNAi) is process by which small interfering RNA/DNA chimera triggers the destruction of mRNA for the original gene.  The discovery work, design, and application of chimera RNAi has been pioneered by Professor Kaoru Saigo and Dr. Kumiko Ui-Tei at the University of Tokyo.  Chimera RNAi has many advantages over the conventional siRNAs.  First, it has been demonstrated to have reliable knock-down for over 10,000 human genes.  Because the human genome is composed of an intricate, genetic network, chimera RNAi's unique design has successfully obviated the off-target effects including microRNA-based influence.  Another advantage of the chimera RNAi technology is its effectiveness at low concentrations (0.5nM to 5nM); only mRNA is destroyed so genomic genes are not affected.  Finally, having both the sense and anti-sense strands consisting RNA/DNA chimera, it offers much greater compound stability for streamlining in vitro and in vivo assays and applications while minimizing interferon induction and other adverse reactions.

Bioinformatics

Product By Gene ID	9139
Alternate Names	core-binding factor, runt domain, alpha subunit 2; translocated to, 2 EHTDKFZp313F2116 ETO homolog on chromosome 20 ETO homologous on chromosome 20 MTG8-like protein MTG8-related protein 1 MTGR1p85 myeloid translocation gene-related protein 1 Myeloid translocation-related protein 1 protein CBFA2T2 ZMYND3

Research Areas for MTGR1

Find related products by research area and learn more about each of the different research areas below.

Cancer
Tumor Suppressors